Marksans Pharma Ltd share price logo

Marksans Pharma Ltd Share Price

(MARKSANS)

Small Cap

Healthcare Sector

₹222.47▲0.75%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Marksans Pharma Performance

  • Day's Low

    Day's High

    ₹220.39
    Day's Price Range
    ₹229.3

  • 52 Week's Low

    52 Week's High

    ₹130
    52-Week Price Range
    ₹358.7
1 Month Return+ 10.05 %
3 Month Return-25.01 %
1 Year Return+ 40.8 %
Previous Close₹224.14
Open₹226.00
Volume7.53L
Upper Circuit₹268.96
Lower Circuit₹179.31
Market Cap₹10,081.53Cr

Marksans Pharma Fundamentals

P/E Ratio

27.36

PEG Ratio

28.5

Market Cap

₹10,081.53 Cr

P/B Ratio

5.62

EPS

6.95

Dividend Yield

0.4

Sector

Pharmaceuticals

ROE

11.46

Marksans Pharma Analyst Rating

based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts offering long term price targets for Marksans Pharma. An average target of ₹299.33

Source: S&P Global Market Intelligence

Marksans Pharma Share analysis

Marksans Pharma price forecast by 3 analysts

Upside of34.55%

High

₹323

Target

₹299.33

Low

₹265

Marksans Pharma target price ₹299.33, a slight upside of 34.55% compared to current price of ₹222.47. According to 3 analysts rating.

Source: S&P Global Market Intelligence

Key events for Marksans Pharma Ltd

  • Marksans Pharma to Participate in Investor Conference - 21 Mar, 2025

    Marksans Pharma Limited will engage stakeholders at the Motilal Oswal India Ideation Conference on March 25, 2025, in Mumbai. The company focuses on generic pharmaceutical formulations and serves a global market. YTD price performance is down 32.06%, with a current market cap of 91.92B INR.

  • Marksans Pharma Gains TGA Approval for Goa Facility - 20 Mar, 2025

    Marksans Pharma's manufacturing facility in Goa has received approval from the Australian TGA to produce solid dosage forms for the Australian market, boosting its growth prospects.

  • Marksans Pharma Secures Baclofen Approval in UK - 19 Mar, 2025

    Marksans Pharma's subsidiary, Relonchem, received marketing authorization for Baclofen 10 mg tablets from UK MHRA, enhancing its presence in the UK market. The company reported significant revenue growth and improved profit margins, indicating strong performance in key markets.

  • Marksans Pharma Credit Rating Upgraded - 05 Mar, 2025

    Marksans Pharma Limited has received an upgrade in its credit rating from India Ratings, improving its long-term debt rating to IND AA- with a stable outlook. This upgrade reflects the company's financial stability and may enhance its market reputation and borrowing capacity.

  • Marksans Pharma Gains UK Approval for Pain Relief Tablets - 25 Feb, 2025

    Marksans Pharma's subsidiary, Relonchem, has received marketing authorization in the UK for Ibuprofen and Paracetamol tablets, strengthening its presence in the OTC pain relief market.

Insights on Marksans Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, MARKSANS stock has moved up by 389.0%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, 78.29 Cr → 104.56 Cr (in ₹), with an average increase of 9.2% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 3.02% to 3.15% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 576.54 Cr → 709.7 Cr (in ₹), with an average increase of 6.7% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 10.43% to 11.07% in Dec 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 43.87% of holdings in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 61.9% return, outperforming this stock by 21.1%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 30.71% to 29.87% in Dec 2024 quarter

Marksans Pharma Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹586.13Cr (-)₹560.01Cr (↓4.46%)₹590.62Cr (↑5.47%)₹641.92Cr (↑8.69%)₹681.85Cr (↑6.22%)
Net Income₹82.97Cr (-)₹77.64Cr (↓6.42%)₹89.07Cr (↑14.72%)₹97.76Cr (↑9.76%)₹105.07Cr (↑7.48%)
Net Profit Margin14.16% (-)13.86% (↓2.12%)15.08% (↑8.80%)15.23% (↑0.99%)15.41% (↑1.18%)
Value in ₹ crore
Details2021202220232024
Total Assets₹741.13Cr (-)₹966.49Cr (↑30.41%)₹1,346.73Cr (↑39.34%)₹1,518.05Cr (↑12.72%)
Total Liabilities₹141.41Cr (-)₹181.82Cr (↑28.58%)₹235.40Cr (↑29.47%)₹295.34Cr (↑25.46%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹107.58Cr (-)₹106.92Cr (↓0.61%)₹55.97Cr (↓47.65%)₹51.73Cr (↓7.58%)₹34.05Cr (↓34.18%)

Marksans Pharma Index Inclusions

BSE Small-Cap

₹46,638.13

-0.35 (▲-165.52%)

BSE Healthcare

₹41,421.50

-0.12 (▲-48.19%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Marksans Pharma Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
43.87%
0.00
Foreign Institutions
11.07%
6.20
Mutual Funds
3.15%
4.04
Retail Investors
29.87%
-2.74
Others
12.04%
0.61

Marksans Pharma Key Indicators

Details20202021202220232024
Earning Per Share (₹)2.955.834.565.856.95
Details20202021202220232024
Return On Equity %7.0717.2915.0210.8511.46
Details20202021202220232024
Return On Assets %20.131.8419.119.7720.66
Details20202021202220232024
Book Value Per Share (₹)15.5421.6627.138.5145.57

Marksans Pharma Valuation

Marksans Pharma in the last 5 years

  • Overview

  • Trends

Lowest (4.67x)

April 1, 2020

Today (27.36x)

March 28, 2025

Industry (53.18x)

March 28, 2025

Highest (46.60x)

January 24, 2018

LowHigh

Marksans Pharma Earnings and Dividends

  • Marksans Pharma Ltd Earnings Results

    Marksans Pharma Ltd’s net profit jumped 25.61% since last year same period to ₹104.56Cr in the Q3 2024-2025. On a quarterly growth basis, Marksans Pharma Ltd has generated 8.11% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Marksans Pharma Ltd Dividends May,2024

    In the quarter ending March 2024, Marksans Pharma Ltd has declared dividend of ₹0.60 - translating a dividend yield of 0.49%.

    Read More about Dividends

Marksans Pharma Technicals Summary

Bearish

Neutral

Bullish

Bearish

Marksans Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Marksans Pharma Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Marksans Pharma Ltd
Marksans Pharma Ltd
BUY₹10,081.53 Cr300.1%0.51₹314 Cr₹2,177 Cr
Parmax Pharma Ltd
Parmax Pharma Ltd
NA₹15.80 Cr32.8%0.99NANA
Bharat Immunological & Biological Corporation Ltd
Bharat Immunological & Biological Corporation Ltd
NA₹86.49 Cr48.83%0.73NANA
Quest Laboratories Ltd
Quest Laboratories Ltd
NA₹167.89 Cr-6.09%0.58NANA
Kerala Ayurveda Ltd
Kerala Ayurveda Ltd
NA₹422.58 Cr171.91%0.81-₹1 Cr₹107 Cr
See all

About Marksans Pharma

Marksans Pharma Limited is a public limited company that specializes in research, manufacture, marketing and sale of pharmaceutical formulations. Established in April 1982, the Company has its research and development centers located in Verna Goa and Navi Mumbai. On 30th March 2015, they issued and allotted 24006494 equity shares of ₹1 each to qualified institutional buyers for ₹54.67 per share under QIP. On 7th February 2015, the Company decided to redeem 1350000 cumulative redeemable preference shares of face value ₹100 each out of profits in tranches before due date of redemption, which was decided to be 27th March 2018. 50000 Bonds of USD 1000 value each were issued during the financial year 2015, out of which 49939 Bonds were bought and extinguished by the Company. 150000 preference shares of ₹100 each were redeemed at par in 2017 and the issued, subscribed and paidup preference share capital was reduced to 1100000 of ₹100 each. Marksans Pharma Limited is a long-standing public limited company offering research, manufacture, marketing and sale of pharmaceutical formulations.

Revenue: ₹681.85Cr as on December 2024 (Q4 24)
Net Profit: ₹105.07Cr as on December 2024 (Q4 24)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
OrganisationMarksans Pharma
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Marksans Pharma Ltd

What is Marksans Pharma Ltd price today?

Marksans Pharma Ltd share price today stands at ₹222.47, Open: ₹226, Previous Close: ₹224.14, High: ₹229.3, Low: ₹220.39, 52 Week High: ₹358.7, 52 Week Low: ₹130.

How to Buy Marksans Pharma Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Marksans Pharma Ltd shares

What are today's traded volumes of Marksans Pharma Ltd?

Today's traded volume of Marksans Pharma Ltd(MARKSANS) is 7.53L.

What is today's market capitalisation of Marksans Pharma Ltd?

Today's market capitalisation of Marksans Pharma Ltd(MARKSANS) is ₹10081.53Cr.

What is the 52 Week High and Low Range of Marksans Pharma Ltd?

Marksans Pharma Ltd (MARKSANS)
Price
52 Week High
₹358.7
52 Week Low
₹130

How much percentage Marksans Pharma Ltd is down from its 52 Week High?

Marksans Pharma Ltd (MARKSANS) share price is ₹222.47. It is down -37.98% from its 52 Week High price of ₹358.7

How much percentage Marksans Pharma Ltd is up from its 52 Week low?

Marksans Pharma Ltd (MARKSANS) share price is ₹222.47. It is up 71.13% from its 52 Week Low price of ₹130